Tag: Medication

The NFXF Conference, Research Opportunities, and a Fragile X Q&A

NFXF Webinar Recap In case you don’t have time, or would prefer the information in written form, we are now providing NFXF Webinar recaps. These are summaries of the webinars, using paraphrases rather than word-for-word dictation of the actual webinars. For this webinar, we were joined by Dr. Craig Erickson of the Cincinnati Fragile X



Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

by NFXF

PRESS RELEASE FROM ZYNERBA PHARMACEUTICALS Devon, PA, , April 23, 2018 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced an oral presentation to be given at the16th NFXF (National Fragile



Insight on Evidence-based Medical and Therapeutic Intervention

by NFXF

A discussion for parents of children with special developmental needs about evidence, consensus and anecdotal-based interventions. After more than four decades of working with parents of children with special developmental needs, I’ve learned that they often find it difficult to know what the best approaches or interventions are to help their children. Conflicting statements, recommendations



Dr. Craig Erickson Discusses the Drug Acamprosate for the Treatment of FXS

by NFXF

Acamprosate, a drug used to treat alcohol abuse, improves communication and social behaviors associated with a common form of autism. IU autism researcher Craig Erickson, MD, will discuss his ongoing study of acamprosate and Fragile X syndrome, the most frequent, single genetic cause of autism. Listen or download podcast Dr. Erickson is assistant professor of